METAP2 and breast cancer: Because so many of our screen hits were supported by literature and all nine hits (Ctsf, Metap1, Metap2, MMP17, Pmpca, Pmpcb, Psmd13, Usp46, and Usp7) that we chose to validate individually showed impaired MTT viability and competitive growth in PyB6-TA and PyMG-TA breast cancer cells (Figure 6), we are confident that we established a robust and successful screen.